Effective induction of high-titer antibodies by viral vector vaccines

被引：125

作者：

Draper, Simon J. ^{[1
]}

Moore, Anne C. ^{[1
]}

Goodman, Anna L. ^{[1
]}

Long, Carole A. ^{[2
]}

Holder, Anthony A. ^{[3
]}

Gilbert, Sarah C. ^{[1
]}

Hill, Fergal ^{[4
]}

Hill, Adrian V. S. ^{[1
]}

机构：

[1] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England

[2] NIAID, Lab Malaria & Vector Res, US NIH, Rockville, MD 20852 USA

[3] Natl Inst Med Res, Div Parasitol, London NW7 1AA, England

[4] Imaxio, F-69007 Lyon, France

来源：

NATURE MEDICINE | 2008年 / 14卷 / 08期

基金：

英国医学研究理事会; 英国惠康基金;

关键词：

D O I：

10.1038/nm.1850

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Protein-in-adjuvant vaccines have shown limited success against difficult diseases such as blood-stage malaria. Here we show that a recombinant adenovirus-poxvirus prime-boost immunization regime (known to induce strong T cell immunogenicity) can also induce very strong antigen-specific antibody responses, and we identify a simple complement-based adjuvant to further enhance immunogenicity. Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro.

引用

页码：819 / 821

页数：3

共 16 条

[1] Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region
Ahlborg, N
Ling, IT
Howard, W
Holder, AA
Riley, EM
[J]. INFECTION AND IMMUNITY, 2002, 70 (02) : 820 - 825
[2] Complement inhibitor C4b-binding protein -: friend or foe in the innate immune system?
Blom, AM
Villoutreix, BO
Dahlbäck, B
[J]. MOLECULAR IMMUNOLOGY, 2004, 40 (18) : 1333 - 1346
[3] C4b-binding protein (C4BP) activates B cells through the CD40 receptor
Brodeur, SR
Angelini, F
Bacharier, LB
Blom, AM
Mizoguchi, E
Fujiwara, H
Plebani, A
Notarangelo, LD
Dahlback, B
Tsitsikov, E
Geha, RS
[J]. IMMUNITY, 2003, 18 (06) : 837 - 848
[4] Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen
Bruña-Romera, O
González-Aseguinolaza, G
Hafalla, JCR
Tsuji, M
Nussenzweig, RS
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) : 11491 - 11496
[5] Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
Catanzaro, Andrew T.
Koup, Richard A.
Roederer, Mario
Bailer, Robert T.
Enama, Mary E.
Moodie, Zoe
Gu, Lin
Martin, Julie E.
Novik, Laura
Chakrabarti, Bimal K.
Butman, Bryan T.
Gall, Jason G. D.
King, C. Richter
Andrews, Charla A.
Sheets, Rebecca
Gomez, Phillip L.
Mascola, John R.
Nabel, Gary J.
Graham, Barney S.
[J]. JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (12) : 1638 - 1649
[6] Asexual blood-stage malaria vaccine development: facing the challenges
Genton, Blaise
Reed, Zarifah H.
[J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2007, 20 (05) : 467 - 475
[7] Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes
Gilbert, SC
Schneider, J
Hannan, CM
Hu, JT
Plebanski, M
Sinden, R
Hill, AVS
[J]. VACCINE, 2002, 20 (7-8) : 1039 - 1045
[8] Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response
Hensmann, M
Li, C
Moss, C
Lindo, V
Greer, F
Watts, C
Ogun, SA
Holder, AA
Langhorne, J
[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (03) : 639 - 648
[9] Pre-erythrocytic malaria vaccines: towards greater efficacy
Hill, AVS
[J]. NATURE REVIEWS IMMUNOLOGY, 2006, 6 (01) : 21 - 32
[10] Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400

← 1 2 →